There was a divergence of opinion among the pharmaceutical company interviewees about the readiness of the science base for cocaine pharmacotherapies. Representatives of two companies expressed skepticism about the readiness of the science base. One representative indicated that current limitations stem from a lack of understanding regarding the biological and genetic basis of addiction. A representative of a different company indicated that the current science base for achieving long-term efficacy for cocaine abuse and addiction is very weak. Furthermore, scientists from one company judged that the probability of a scientific breakthrough in the area of cocaine abuse and addiction in the near future is very low. In contrast, representatives of another pharmaceutical company indicated strongly that the science base is ready, and consequently that it is no longer a market barrier to development of cocaine pharmacotherapies. This company also reported that it had successfully identified several drug candidates that exhibited cocaine blocking activities in both in vivo and in vitro models. The extent of company interviews was limited by the scope of this project.